Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jessica R. May"'
Autor:
Svenja Petersohn, Bradley McGregor, Sven L Klijn, Jessica R May, Flavia Ejzykowicz, Murat Kurt, Matthew Dyer, Bill Malcolm, Sebastien Branchoux, Katharina Nickel, Saby George, Sonja Kroep
Publikováno v:
Journal of Comparative Effectiveness Research (2023)
Aim: Network meta-analyses (NMAs) increasingly feature time-varying hazards to account for nonproportional hazards between different drug classes. This paper outlines an algorithm for selecting clinically plausible fractional polynomial NMA models.
Externí odkaz:
https://doaj.org/article/f4ab129d0b404efd8c4b62efb4d76780
Autor:
Shanlian Hu, Zhiliu Tang, James P. Harrison, Nadine Hertel, John R. Penrod, Jessica R. May, Ariadna Juarez-Garcia, Orban Holdgate
Publikováno v:
PharmacoEconomics - Open. 7:273-284
Autor:
Esra Çakar, César Oniangue-Ndza, Ralph P. Schneider, Sven L. Klijn, Ursula M. Vogl, Christian Rothermundt, Jessica R. May
Publikováno v:
PharmacoEconomics - Open.
Autor:
Bradley McGregor, Daniel M. Geynisman, Mauricio Burotto, Cristina Suárez, Maria T. Bourlon, Pedro C. Barata, Shuchi Gulati, Stephen Huo, Flavia Ejzykowicz, Steven I. Blum, Viviana Del Tejo, Melissa Hamilton, Jessica R. May, Ella X. Du, Aozhou Wu, Pavol Kral, Cristina Ivanescu, Andi Chin, Keith A. Betts, Chung-Han Lee, Toni K. Choueiri, David Cella, Camillo Porta
Publikováno v:
European Urology Oncology.
Autor:
Shannon Cope, Keith Chan, Harlan Campbell, Jenny Chen, John Borrill, Jessica R. May, William Malcolm, Sebastien Branchoux, Katrin Kupas, Jeroen P. Jansen
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
Network meta-analysis (NMA) of time-to-event outcomes based on constant hazard ratios (HRs) can result in biased findings when the proportional hazards (PH) assumption does not hold in a subset of trials. We aimed to summarize the published non-PH NM
Autor:
Jessica R. May, Derek H. Tang, Dinesh Mishra, Gary M. Oderda, Rohit Mistry, S Bhattacharyya, Devarshi Bhattacharyya, Kate Young, Gaurav Suri, Anand A. Dalal, Joseph Biskupiak, Robert Hettle, Diana I. Brixner
Publikováno v:
Current Medical Research and Opinion. 34:2143-2150
The combination of a cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitor with the aromatase inhibitor letrozole is a safe and effective alternative to letrozole monotherapy for first-line hormone receptor-positive (HR+)/human epidermal growth factor
Autor:
Rohit Mistry, Anand A. Dalal, Jessica R. May, Joseph Biskupiak, Kate Young, Dinesh Mishra, Derek H. Tang, Diana I. Brixner, S Bhattacharyya, Gary M. Oderda, Gaurav Suri, Devarshi Bhattacharyya
Publikováno v:
Journal of managed carespecialty pharmacy. 24(6)
U.S. regulatory approvals of the cyclin-dependent kinase 4 and 6 (CDK 4/6) inhibitors ribociclib and palbociclib as add-ons to letrozole greatly enhance the prospects for treating postmenopausal women with hormone receptor-positive (HR+)/human epider
Autor:
Kirill Feldman, Paul E. Smith, Denis V. Anokhin, Molly M. Stevens, David E. Clarke, Dimitri A. Ivanov, Jessica R. May, Yaroslav Odarchenko, Cristina Gentilini
Publikováno v:
RSC Adv.. 4:2096-2102
Tensile deformation was applied to the naturally produced poly-γ-glutamic acid, which can be enzymatically degraded and is, therefore, of interest for biomedical use. However, natural polyamino acids have a similar chemical structure to synthetic po
Autor:
Molly M. Stevens, Boon-Heng Lee, Silvia Goldoni, E. Thomas Pashuck, Cristina Gentilini, Jessica R. May, David E. Clarke, Yixiang Dong
Publikováno v:
Advanced healthcare materials. 1(3)
Poly(γ-glutamic acid) (γ-PGA) is a biocompatible, enzymatically-degradable, natural polymer with a higher resistance to hydrolysis than polyesters commonly used for tissue engineering scaffolds such as poly(L-lactide) (PLLA). Notably, γ-PGA's free